Drug Trial Radar · NCT02489903
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Jun 2015
Primary completion
Dec 6, 2021
Study completion Dec 6, 2021
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.
Conditions
- Small Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Neuroendocrine Tumors
- Ovarian Epithelial Cancer
Interventions
RRx-001Drug
CisplatinDrug
EtoposideDrug
CarboplatinDrug
IrinotecanDrug
VinorelbineDrug
DoxilDrug
GemcitabineDrug
TaxaneDrug
PaclitaxelDrug
Nab-PaclitaxelDrug
PemetrexedDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From start of treatment through death for up to 64 months from Start of Treatment.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
VA Connecticut Cancer Center
West Haven, Connecticut
Memorial Hospital of South Bend
South Bend, Indiana
Baptist Health
Lexington, Kentucky
Walter Reed National Military Medical Center
Bethesda, Maryland
Henry Ford Allegiance Health
Jackson, Michigan
Washington University
St Louis, Missouri
University of Cincinnati Cancer Institute
Cincinnati, Ohio
Virginia Cancer Specialists
Fairfax, Virginia
West Virginia University
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.